|
Ion Channels
Offer Possible Biotech/Neurotech Synergy
by Warren Grill, senior technical editor, and James Cavuoto,
editor
Since the beginning of the neurotechnology industry, the field has
defined itself with electronic devices to stimulate or record from
neural tissue. The biotech industry, by contrast, has defined itself
with chemical and genetic engineering methods of modulating the
behavior of cells, tissues, and organs. A common technique is to
identify chemical receptors on specific targeted cells that respond
to specific genetically engineered compounds.
While these two approaches have generally been distinct and independent
endeavors, there is at least one area of overlap between neurotech
and biotech applications, and that involves ion channel kinetics.
Ion channels are gates in the membrane of neural cells that regulate
the concentration of charged elements such as potassium, calcium,
or sodium inside and outside the cell membrane.
Thus, biological or pharmacological techniques that affect the kinetics
of ion transport across a neural membrane become, in essence, a
form of electrical stimulation in that they produce electrical activationor
deactivationof neurons just as if a stimulating electrode
had produced the change in ion channel kinetics. Indeed, this area
of overlap represents perhaps one of the most promising synergies
between traditionally device-oriented neurotechnology and traditionally
molecular-oriented biotechnology.
The value of ion-channel kinetics to neurotechnology applications
is the potential to deliver stimulation only to specific classes
of neural cells, instead of broadly to all cells in the vicinity
of the stimulating electrodes. Conversely, the value of neurotechnology
to biotech firms and researchers pursuing ion-channel approaches
is the availability of electronic models that help monitor, diagnose,
and predict the resulting behavior of neural cells and brain subsystems.
For example, one important aspect of neurotechnology is the use
of electrical stimulation to activate the nervous system. Although
electrical methods have been developed to block transmission of
activity in nerve fibers, electrical techniques to reversibly silence
neurons are lacking. Two different research teams have recently
published reports in the Journal of Neuroscience that present genetic
engineering methods of reversibly silencing selected neurons.
Lechner and colleagues from The Salk Institute, in La Jolla, CA
used exogenously expressed allostatin receptors and G-protein coupled
potassium channels to modulate the excitability of cultured cortical
neurons. Following application of allostatin, the receptors were
activated and, through a G-protein mediated second messenger cascade,
activated the potassium channels. The activated potassium channels
hyperpolarized the cell membrane and decreased neuronal excitability
by a factor of 10.
The decrease in excitability occurred within minutes of the application
of allostatin, and similarly was reversed within minutes of allostatin
removal. These results thus demonstrate a novel genetic technique
to quickly and reversibly reduce the excitability of neurons. Further,
as the allostatin receptor is not normally present in mammalian
neurons, its selective expression could be used to limit effects
to targeted groups of neurons.
A similar approach was reported by Slimko and colleagues from California
Institute of Technology. They expressed ivermectin-sensitive chloride
channels in cultured hippocampal neurons. Following application
of ivermectin, the chloride channels opened, decreasing the membrane
resistance and allowing chloride ions to flow into the cells. The
influx of chloride hyperpolarized the cell membrane and, in combination
with the decrease in membrane resistance, reduced excitability of
the cells.
The time course of the influx of chloride and decrease in membrane
resistance was dependent on the concentration of ivermectin applied.
At high concentration the chloride conductance was activated in
less than one second following application of ivermectin, but at
a 100-fold lower concentration the conductance took hundreds of
seconds to activate completely. The time to reverse the ivermectin-activated
conductance, however, was between one and eight hours.
These novel biotech tools enable the modulation of the excitability
of selected populations of neurons. Such methods will prove exceptionally
important in determining the role of specific neurons in regulation
of behavior, and could be a harbinger of future treatments where
aberrantly firing neurons are switched off with genetic techniques.
There are currently several commercial biotech firms working on
ion-channel approaches to nervous system modulation. Neurobiological
Technologies Inc. of Richmond, CA is a drug discovery firm concentrating
on neuroprotective and neuromodulatory agents. The firm has developed
potential drugs that control the flow of calcium ions across the
neural membrane in certain forms of neuropathology.
Another firm, NeurogesX, Inc. of San Carlos, CA, has identified
specific receptors in pain fibers that can be blocked, using a chemical
agent called capsaicin, without blocking other sensory and motor
fibers. Synaptic Pharmaceutical Corp. of Paramus, NJ, has used its
expertise in G-protein-coupled receptors to identify receptors in
specific neural cells that can be blocked for potential treatment
of disorders such as incontinence and depression.
As products such as these reach later stages of commercial development,
and as neurostimulation devices become more compact, localizable,
and integrated with the extracellular matrix within the nervous
system, the opportunities for interaction between biotech and neurotech
device approaches to the nervous system will expand considerably.
Presumably, the opportunities for business and commercial synergy
will expand as well.
|
|